title: Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
abstract: The aim of this study was to evaluate changes in lipid profiles in patients with type 2 diabetes after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin and other lipid-altering therapies. A total of 305 patients were enrolled in this open-label study. Patients had been taking stable dosages of rosiglitazone and statins for > 90 days. At baseline, patients discontinued rosiglitazone and started pioglitazone 30 mg/day, but continued statins and other lipid-altering therapies. The primary end point was change from baseline in fasting triglyceride levels. At 17 weeks after treatment conversion, patients had significant reductions in triglycerides (-15.2%), total cholesterol (-9.0%), and low-density lipoprotein (LDL) particle concentration (-189 nmol/L), and increases in LDL cholesterol (+2.2%), high-density lipoprotein (HDL) cholesterol (+1.8%), and LDL particle diameter (+0.23 nm). In conclusion, after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin therapy, patients with type 2 diabetes had marked improvements in lipid profiles along with stable glycaemic control.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, Wayne State University School of Medicine, Detroit, MI, USA.
authors.forename: Paulos
authors.initials: P
authors.lastname: Berhanu
authors.forename: Mark S
authors.initials: MS
authors.lastname: Kipnes
authors.forename: Mehmood A
authors.initials: MA
authors.lastname: Khan
authors.forename: Alfonso T
authors.initials: AT
authors.lastname: Perez
authors.forename: Stuart F
authors.initials: SF
authors.lastname: Kupfer
authors.forename: Robert C
authors.initials: RC
authors.lastname: Spanheimer
authors.forename: Seleshi
authors.initials: S
authors.lastname: Demissie
authors.forename: Penny R
authors.initials: PR
authors.lastname: Fleck
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002097:C-Reactive Protein / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D001786:Blood Glucose; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D014280:Triglycerides; D000077154:Rosiglitazone; D002097:C-Reactive Protein; D002784:Cholesterol; D000077205:Pioglitazone